Goncalves Joana 4

What Happened
Joana Goncalves, Chief Medical Officer of Oruka Therapeutics (ORKA), received equity compensation on 2026-01-23 consisting of 32,500 shares granted as an award and a derivative award (option) covering 130,000 shares. Both were reported as acquired at $0.00, which indicates equity compensation rather than a market purchase. Total awarded equity equals 162,500 shares (32,500 restricted shares + option for 130,000 underlying shares).

Key Details

• Transaction date: 2026-01-23. Acquisition price: $0.00 for both items.
• Award breakdown: 32,500 shares (award); 130,000-share derivative (option).
• Vesting: the 32,500 award vests 1/16 of the shares each March 14, June 14, September 14 and December 14 (or the preceding trading day) — see footnote F1. The 130,000-share option vests 1/48 of the underlying shares monthly beginning January 1, 2026 — see footnote F2.
• Shares owned after transaction: not specified in this Form 4 filing.
• Filing timeliness: Reported same day (Period of Report and Filed date 2026-01-23), so appears timely.
• Transaction type codes: reported as A (grant/award); the 130,000 is a derivative/option (not an immediate sale or market purchase).

Context
These entries represent typical equity compensation—restricted shares and an option grant—not a cash purchase or sale. The option vests monthly (1/48 per month), meaning the underlying shares become exercisable gradually starting January 2026. No immediate sale or cashless exercise is reported here. Such grants are common for executives and do not by themselves indicate buying or selling sentiment.